Journal Article

Magnetic resonance imaging-guided single-fraction preoperative radiotherapy for early-stage breast cancer (the RICE trial): feasibility study

Lau, Eddie, Loh, Su-Wen, Yeo, Belinda, Singh, Nabita, Scott, Andrew M., Kron, Tomas, McAuley, Rosly, Brown, Kerryn, Moe, Aung Aung Kywe, Ireland-Jenkins, Kerryn, Chao, Michael, Tacey, Mark, Mann, Bruce, McDermont, Leah, Qadir, Ayyaz, Ooi, Wei Ming, Cahoon, Glenn, Uribe, Sergio, Foroudi, Farshad, Dean, Jenna, Ng, Suat

2024

Overview

Background Over the past decade, the adoption of screening programs, digital mammography, and magnetic resonance imaging (MRI) has increased early-stage breast cancer diagnosis rates. Mortality rates have decreased due to early detection and improved treatments, including personalized therapies. Accelerated partial-breast irradiation (APBI) is emerging as a convenient and effective treatment for some patients, with studies exploring its preoperative use. Preoperative APBI, especially with MRI guidance, offers improved tumor targeting and potentially reduced side effects. Magnetic Resonance Imaging-Guided Single-Fraction Pre-Operative Radiotherapy for Early-Stage Breast Cancer (RICE trial) aims to assess the feasibility and efficacy of MRI-guided single-dose radiotherapy (RT) for early-stage breast cancer. Methods The RICE study is a prospective, single-arm study evaluating single-fraction preoperative, APBI treatment for patients with early-stage breast cancer using a magnetic resonance imaging linear accelerator (MRI linac). Eligible patients enrolled in this study will have a core biopsy to confirm estrogen receptor-positive and HER2-negative sub-type. RT planning will use a planning computed tomography (CT) co-registered with a MRI with the patient in either the supine or prone position. For the diagnostic workup, [18F] fluorodeoxyglucose positron emission tomography/CT ([18F] FDG PET/CT) and [18F] fluoroestradiol positron emission tomography/CT ([18F] FES PET/CT) will be performed prior to treatment. Thirty patients will receive a single ablative RT dose of 21 Gray to the tumor. Pre-treatment and post-treatment MRI scans will be acquired at baseline and 5 weeks post-RT respectively. Breast-conserving surgery will be scheduled for 6 weeks after APBI treatment using the MRI linac. The primary study endpoint is the successful administration of a single fraction of preoperative breast RT under the guidance of an MRI linac. Secondary endpoints include evaluating the utility of MRI, [18F] FDG PET/CT, and [18F] FES PET/CT as a non-invasive method for assessing treatment response in patients undergoing single-fraction preoperative APBI. Conclusion The RICE trial represents a significant step in breast cancer treatment, offering insights that could lead to treatment protocols with minimized RT appointments and enhanced patient outcomes. Trial registration This trial is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR). Registered 31st of May 2021. Registration number: ACTRN12621000659808 . 

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Adjuvant treatment / Biomedicine / Breast cancer / Cancer / Care and treatment / Diagnosis / Diagnostic imaging / Health aspects / Health Sciences / Lumpectomy / Magnetic resonance imaging / Medical imaging equipment / Medicine / Medicine & Public Health / Morocco / Mortality / Neoadjuvant therapy / Oncology, Experimental / Radiation / Radiation therapy / Radiotherapy / Response / Statistics for Life Sciences / Study Protocol / Sweden / Tomography